{"id":37273,"date":"2025-07-14T15:02:19","date_gmt":"2025-07-14T07:02:19","guid":{"rendered":"https:\/\/flcube.com\/?p=37273"},"modified":"2025-07-14T15:02:20","modified_gmt":"2025-07-14T07:02:20","slug":"eolas-therapeutics-gains-full-rights-to-azd4041-for-opioid-use-disorder-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37273","title":{"rendered":"Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development"},"content":{"rendered":"\n

US-based Eolas Therapeutics has entered into an agreement with its UK partner AstraZeneca (AZ, NASDAQ: AZN<\/a>) to acquire full development rights to the investigational therapy AZD4041, a highly selective orexin-1 receptor antagonist. This move positions Eolas at the forefront of developing potential treatments for opioid use disorder (OUD) and other substance use disorders.<\/p>\n\n\n\n

Drug Development Background<\/strong>
Previously co-developed by Eolas Therapeutics and AstraZeneca with support from the National Institute on Drug Abuse (NIDA) in the United States, AZD4041 targets key neural circuits involved in addiction. The drug has demonstrated preliminary efficacy in preclinical and early-stage clinical studies.<\/p>\n\n\n\n

Future Development Plans<\/strong>
Under the new agreement, Eolas Therapeutics will assume full responsibility for advancing AZD4041 to Phase II clinical trials. The program will continue to receive support from NIDA, ensuring sustained progress toward the goal of addressing unmet needs in the treatment of substance use disorders.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US-based Eolas Therapeutics has entered into an agreement with its UK partner AstraZeneca (AZ, NASDAQ:…<\/p>\n","protected":false},"author":1,"featured_media":37276,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[130,4218,871],"class_list":["post-37273","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-astrazeneca","tag-eolas-therapeutics","tag-nasdaq-azn"],"yoast_head":"\nEolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Eolas Therapeutics has entered into an agreement with its UK partner AstraZeneca (AZ, NASDAQ: AZN) to acquire full development rights to the investigational therapy AZD4041, a highly selective orexin-1 receptor antagonist. This move positions Eolas at the forefront of developing potential treatments for opioid use disorder (OUD) and other substance use disorders.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37273\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development\" \/>\n<meta property=\"og:description\" content=\"US-based Eolas Therapeutics has entered into an agreement with its UK partner AstraZeneca (AZ, NASDAQ: AZN) to acquire full development rights to the investigational therapy AZD4041, a highly selective orexin-1 receptor antagonist. This move positions Eolas at the forefront of developing potential treatments for opioid use disorder (OUD) and other substance use disorders.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37273\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-14T07:02:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-14T07:02:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1407.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37273#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37273\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development\",\"datePublished\":\"2025-07-14T07:02:19+00:00\",\"dateModified\":\"2025-07-14T07:02:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37273\"},\"wordCount\":160,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37273#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1407.webp\",\"keywords\":[\"AstraZeneca\",\"Eolas Therapeutics\",\"NASDAQ: AZN\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37273#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37273\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37273\",\"name\":\"Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37273#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37273#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1407.webp\",\"datePublished\":\"2025-07-14T07:02:19+00:00\",\"dateModified\":\"2025-07-14T07:02:20+00:00\",\"description\":\"US-based Eolas Therapeutics has entered into an agreement with its UK partner AstraZeneca (AZ, NASDAQ: AZN) to acquire full development rights to the investigational therapy AZD4041, a highly selective orexin-1 receptor antagonist. This move positions Eolas at the forefront of developing potential treatments for opioid use disorder (OUD) and other substance use disorders.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37273#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37273\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37273#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1407.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1407.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37273#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development - Insight, China's Pharmaceutical Industry","description":"US-based Eolas Therapeutics has entered into an agreement with its UK partner AstraZeneca (AZ, NASDAQ: AZN) to acquire full development rights to the investigational therapy AZD4041, a highly selective orexin-1 receptor antagonist. This move positions Eolas at the forefront of developing potential treatments for opioid use disorder (OUD) and other substance use disorders.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37273","og_locale":"en_US","og_type":"article","og_title":"Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development","og_description":"US-based Eolas Therapeutics has entered into an agreement with its UK partner AstraZeneca (AZ, NASDAQ: AZN) to acquire full development rights to the investigational therapy AZD4041, a highly selective orexin-1 receptor antagonist. This move positions Eolas at the forefront of developing potential treatments for opioid use disorder (OUD) and other substance use disorders.","og_url":"https:\/\/flcube.com\/?p=37273","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-14T07:02:19+00:00","article_modified_time":"2025-07-14T07:02:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1407.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37273#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37273"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development","datePublished":"2025-07-14T07:02:19+00:00","dateModified":"2025-07-14T07:02:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37273"},"wordCount":160,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37273#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1407.webp","keywords":["AstraZeneca","Eolas Therapeutics","NASDAQ: AZN"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37273#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37273","url":"https:\/\/flcube.com\/?p=37273","name":"Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37273#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37273#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1407.webp","datePublished":"2025-07-14T07:02:19+00:00","dateModified":"2025-07-14T07:02:20+00:00","description":"US-based Eolas Therapeutics has entered into an agreement with its UK partner AstraZeneca (AZ, NASDAQ: AZN) to acquire full development rights to the investigational therapy AZD4041, a highly selective orexin-1 receptor antagonist. This move positions Eolas at the forefront of developing potential treatments for opioid use disorder (OUD) and other substance use disorders.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37273#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37273"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37273#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1407.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1407.webp","width":1080,"height":608,"caption":"Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37273#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1407.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37273","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37273"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37273\/revisions"}],"predecessor-version":[{"id":37275,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37273\/revisions\/37275"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37276"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37273"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37273"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}